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Abstract:
The natural history of PNH clinical subcategories (Classic PNH and aplastic anemia (AA) /PNH syndrome) is still unknown. We retrospectively studied 460 PNH patients diagnosed in 58 French hematological centers from 1950 to 2005.
The median (SE) follow-up time was 6.8 (0.5) years. The median survival time was 22 (2.5) years. We identified 113 patients with Classic PNH, 224 patients with AA-PNH syndrome, and 93 (22%) intermediate patients who did not fit within these 2 categories. At presentation, Classic PNH patients were older, with more frequent abdominal pain and displayed higher levels of GPI-APdeficient granulocytes. A time-dependent improved survival was observed. In classic PNH, diagnoses before 1986 (Hazard Ratio (HR) 3.6; p=0.01) and increasing age (p<0.001) were associated with worse survival prognoses, while use of androgens within the first year after diagnosis was protective (HR 0.17; p=0.01). Transfusions before 1996 (HR 2.7; p=0.007) led to lower survival rates in patients with AA-PNH syndrome, while immunosuppressive treatment was associated with better outcomes (HR 0.33; p=0.03). Evolution to thrombosis affected survival in both subcategories (Classic PNH: HR 7.8, p<0.001; AA-PNH syndrome HR 33.0, p<0.001). Evolution to bi-or pancytopenia for Classic PNH (HR 7.3, p<0.001) and malignancies for AA-PNH syndrome (HR 48.8; p<0.001) were associated with worse outcomes. Although clinical presentation and prognosis factors are different, Classic PNH and AA-PNH syndrome present roughly similar outcomes, mainly affected by complications.
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Introduction:
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells. The disease is diagnosed with hemolytic anemia, marrow failure or episodes of venous thrombosis 1 . PNH is related to a somatic mutation in the phosphatidilinositol Glycan class A (PIG-A), X-linked gene, responsible for a deficiency in glycosyl phosphatidilinositol-anchored proteins (GPI-AP) 2 . The lack of one of the GPI-AP complement regulatory proteins (CD59) leads to hemolysis 3 . Recent studies have focused on inhibiting the complement cascade with encouraging clinical results using Eculizumab, a C5-inhibitor humanized monoclonal antibody 4, 5 . PNH diagnosis has evolved over time. Prior to the past two decades, Ham's test was used. It was based on the increased sensitivity of PNH-affected erythrocytes to complement-mediated lysis 6 . In the late 1980s, flow cytometry (FC) allowed direct quantification of the GPI-AP-deficient cells. FC, the current standard for diagnosis 1 , is a reliable quantitative test, and is more sensitive than Ham's test for the identification of small populations of GPI-AP-deficient cells 7 .
While significant advances have been reported in the detection of the GPI-AP-deficient cells, as well as in the pathophysiology of the disease, the natural history and the identification of survival prognostic factors have been rarely described [8] [9] [10] . From earlier descriptions, the clinical polymorphism of PNH has been recognized by two presentations; one form, predominantly hemolytic without overt marrow failure, referred to Classic PNH 1 , and the other one, with marrow failure, was often described as the aplastic anemia PNH syndrome (AA-PNH) 11 . This dichotomy is used as a working classification, but clinical presentations and evolutions of these two clinical entities have not yet been elucidated. The aim of this study was to better determine, in a sizeable cohort of patients, the presentation at time of diagnosis, the development of complications, the overall survival rate, the risk factors for thrombosis and 
Methods:

Patients and study design
A previous report in 1996 contained data from 220 patients 9 . The present questionnaire was intended to replicate the information collected in the above study carried out in 1995 9 , with more detailed information on successive treatment (Appendix Figure 1 ). The study protocol was approved by the review board of the French Society of Hematology. The study was carried out according to the Helsinki Declaration. The questionnaire was sent to all members of the French Society of Hematology (SFH) and/or the French Association of Young Hematologists (AIH) in January 2005, which requested information from diagnosis to latest news on all patients with PNH that were diagnosed or followed-up in their center. The data were carefully checked for duplicates by the first three letters of the patient's name, surname or maiden name, gender, and date of birth. Of the 220 patients previously reported, 71 had died by the time of the preceding report. Among the latter, 42 patients were completely documented again from diagnosis to death. Among the 149 patients who were still alive, 107 patients were documented again from diagnosis and consequently updated. Thus, the data of 149 patients belonging to the first study were entirely checked and 107 were updated. For patients with discrepancies between the 2 sources of data, the corresponding data were discussed with the referring physician to resolve the discrepancies. In addition, 245 patients who were not in the previous report were documented through the questionnaire. Thus, 465 patients were followed from diagnosis to last followup.
Diagnosis
The diagnosis of PNH was defined by an unequivocal positive Ham's test 6 and/or by FC (patients with more than 5% GPI-AP-deficient polymorphonuclear cells were diagnosed with PNH) 7 . The date of diagnosis was based on the first positive Ham's test or on FC analysis if there was no prior positive Ham's test.
The proportion of GPI-AP deficient granulocytes by FC (clone size), was also collected at diagnosis.
Subcategories of PNH patients at diagnosis
Because of the recent proposed PNH working clinical classification 1 , patients were a priori sub-divided into disease subcategories.
The Classic PNH subcategory includes patients with clinical evidence of intravascular hemolysis but no evidence of bone marrow failure. Patients with a thrombosis at diagnosis were included since this subcategory is associated with propensity to thrombosis 12 . Patients with anemia only (less than 12g/dL) and/or thrombosis at diagnosis were thus defined as Classic PNH. Neutrophils and platelets were per criteria greater than 1,500 cells/mm 3 and 120,000 cells/mm 3 , respectively.
Patients with aplastic anemia-PNH syndrome (AA-PNH syndrome) were diagnosed with, at least, 2 or 3 peripheral blood cytopenias (hemoglobin < 10g/dL, platelets < 80,000 cells/mm 3 , neutrophils <1,000 cells/mm 3 ).
Patients who did not fulfill the last 2 subcategories' criteria were assigned to a subcategory referred to as intermediate PNH.
Patients whose data were insufficient to be assigned to one of the 3 subcategories were not classified.
Investigations
Analyses were performed for the overall population as well as for each of the three individual subcategories of patients. In addition to demographic data, the date of diagnosis and the presence or absence of aplastic anemia preceding PNH were documented. Details of presenting symptoms, as well as thrombosis, infections (more than one documented infections requiring specific treatment), and abdominal pains at diagnosis were also documented. Initial cytopenias were recorded at diagnosis. Patients were classified as anemic if the hemoglobin concentration was below 12 g/dL, neutropenic if the absolute granulocyte count was less than 1,500 cells/mm 3 , and thrombocytopenic if the platelet count was below 150,000 cells/mm 313 . Pancytopenia was defined at diagnosis according to international criteria 14 
Statistical analysis
Description of patients at presentation in the global population and in each of the three subcategories is presented as n/N (%) for qualitative variables and median (interquartile range, IQR) for continuous variables. The distributions of the presentation characteristics were compared between the three subcategories and between Classical PNH and AA-PNH by chi-square test, or Fisher exact test when necessary, for qualitative characteristics and by Kruskal-Wallis (3 subcategories) or Mann-Whitney (2 groups) test for continuous characteristics. All but 6 patients were analyzed in terms of follow-up (5 patients have no follow-up data, and status at last follow-up was the only available data for 1 patient). Survival rates (SE) were estimated by the Kaplan-Meier method in the overall population and in each subcategory 15 . Patients who underwent transplantation were censored at that time. Follow-up time and survival time are presented as median (SE). Survival curves were compared between subcategories through log rank tests 16 . In each subcategory, cumulative incidence of progression to bi-or pancytopenia (except in AA-PNH subcategory), thrombosis, myelodysplastic syndrome or acute leukemia were estimated in a competing-risks setting, with death and transplantation treated as competing events 17 . Cumulative incidence curves were compared using the were diagnosed by FC after this date (Appendix figure 2 ). Patient-and diseasecharacteristics and initial treatments are summarized in Table 1 .
Natural history and complications in the overall population
The median (SE) follow-up time was 6.8 (0.5) years. The median (SE) survival time was 22 (2.5) years. Survival rate estimate (SE) was 76.3% (2.6) at 10 years after diagnosis ( Figure 1A) . Complications encountered in the study population are detailed in 
Patients' Characteristics and outcome according to disease subcategory
One hundred and thirteen patients were classified in the Classic PNH subcategory while 224 presented with an AA-PNH syndrome. Ninety three patients (22%) did not fulfill the criteria for these 2 subcategories and were Patients, disease characteristics at diagnosis and initial treatment of each subcategory are summarized in Table 3 . Per criteria, these patients also differed according to biological parameters (anemia and pancytopenia). In Classic PNH, nearly half of the patients had more than 50% GPI-AP-deficient granulocytes, and abdominal pain was the initial symptomatic manifestation in approximately one third of the patients (versus 12 to 16% in the other subcategories).
Survival curves for each subcategory are depicted in Figure 1B . Survival times in disease subcategories were analyzed according to period of time and showed an improvement in AA-PNH syndrome (Figure 1C) . Cumulative incidence of first thrombosis, bi-or pancytopenia (except for AA-PNH subcategory) and malignant disease are displayed per subcategory in Figure 2 .
There was a trend of a higher occurrence of thrombosis (Figure 2A 
Prognostic factors affecting survival in the 3 disease subcategories
Independent prognostic factors affecting overall survival in each subcategory are presented in Table 4 . Thrombosis as a complication was found to be strongly associated with worse prognosis in each of the three subcategories (more strongly associated in AA-PNH patients than in Classic PNH patients). Notwithstanding the interest of studying disease subcategory, it should be reminded that the main complications that impact survival include thromboses, infection and evolution to MDS/leukemias. Myelodysplastic syndrome and acute myeloid leukemia are classic but rare complications of PNH. They occurred in similar proportions as in a previously published paper 10 , with a more than 100-fold increased risk compared to age-matched controls.
The prevalence of recurrent documented infections requiring specific treatment largely exceeded our first estimates 9 (40% of the patients, second cause of death in our population) and confirms the joint American-Japanese study results, in which 20% of Duke patients developed severe infections during follow-up 10 .
Thromboses remain a major life threatening complications affecting outcomes in the overall population, as well as in each of the disease subcategories. One third of the patients suffered thrombotic events in hepatic, cerebral, or deep limb veins [8] [9] [10] . The cumulative incidence of this complication was nearly 37%, in Classic PNH 10 years after diagnosis, but also nearly 30% in AA-PNH syndrome 10, 12, 24 . Risk factors for thrombosis included old age, thrombosis at diagnosis, transfusions, and lack of immunosuppressive therapy.
Warfarin, given as prophylaxis, was also associated with an increased thrombotic risk. This provocative result does not ensure that warfarin increases the risk of thrombosis. It may illustrate the fact that higher risk patients were more likely to be placed on warfarin. However, our study is retrospective and does not allow us to ascertain the reason why these patients were placed on warfarin.
The cause of the thrombotic tendency in PNH is not clear and may be multi factorial. Other groups also reported new thrombosis events (TE) as well as progression of existing TE in patients with PNH, despite the use of anticoagulants and/or anti-aggregative agents 24, 25 . One retrospective study showed a potential role of Warfarin in thrombosis prophylaxis, with 2 serious hemorrhages in 100 patients years of warfarin therapy 12 . The risk for fatal hemorrhage in PNH patients with chronic anticoagulant therapy is mainly related to the frequent occurrence of thrombocytopenia 12, 24 . The complement inhibitor eculizumab 4,5 , able to treat hemolysis-related anemia, also seemed to reduce the risk of clinical thromboembolism; but thrombosis prophylaxis was not the primary objective of this retrospective study 26 . Prophylaxis against thromboembolism, which is still an issue of debate 1 
, could not have been
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From scientifically assessed outside the setting of a prospective randomized trial that could assess whether or not Eculizumab with or without warfarin initiation and/or continuation truly lowered the incidence of thrombosis or relapse thereof. Although immunosuppressive therapy is known to control immune attack, it also seems to decrease the risk of thromboembolism for reasons that are not clear. Finally, concerning the size of the PNH clone, we found a correlation between thromboembolism complications and larger size of the PNH clone (>50%) (HR: 3.2; 95%CI 1.4-7.5; p=0.004). However, our analysis is limited by the fact that the size of the clone was known for only 74% of the patients who were diagnosed by flow cytometry, corresponding to 35% of the overall population. For that reason, clone size was not introduced in the proportional hazard model to study independent factors of thrombosis occurrence.
The protean manifestations of PNH with classical PNH 27 and AA-PNH syndrome 11 have long-been recognized. The joint American-Japanese study confirmed 2 different presentations of the disease and a panel of experts proposed this dichotomy as a working classification for the disease 1, 10 . Our cohort allows the analysis of these 2 different PNH subcategories. However, sixty-one patients presented with hemolytic anemia (but with at least one other cytopenia, and without bi-or pancytopenia according to AA-PNH definition) and 32 patients presented without anemia at diagnosis (and no bi-or pancytopenia according to AA-PNH definition); these patients were included in the intermediate subcategory (93 patients, 21.6%). Thus nearly one out of 5 patients has either hemolytic anemia or one other cytopenia that could easily suggest a diagnosis of PNH, but 32 patients had isolated neutropenia and/or thrombocytopenia, a more unusual presentation. We nevertheless decided to follow the stringent criteria for classical and AA-PNH syndrome proposed by the international expert group 10 for criteria consistency between reports.
Hematological characteristics at diagnosis were per definition different and the
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The overall time-dependent improved survival was observed in all disease subcategories, but was not significant in Classical and Intermediate PNH. This is likely to be due to a lack of statistical power as a result of the limited number of deaths in those 2 subcategories (hazard ratios related to time trend within these subcategories were quite similar to those one estimated in the overall population). 6 (1.3-10.3) , 0.010 0.89 (0.74) ‡ 4.1 (1.0-16.9 ), 0.045
Age at diagnosis
Between 40 and 55 years 5. 4 (1.9-15.7) , <0.0001
More than 40 years 1.7 (0.11) ‡ More than 55 years 21.4 (6.6-68.7), <0. 
